 Zalcitabine and didanosine are both obligate chain terminators, that have been developed for anti-HIV treatment.Unfortunately, both drugs lack selectivity and therefore cause side-effects.Further modification of the dideoxy framework led to the development of 2´,3´-didehydro-3´-deoxythymidine (stavudine, d4T).